NASDAQ:OYST Oyster Point Pharma (OYST) Stock Price, News & Analysis → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free OYST Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$11.17▼$11.1750-Day Range$11.08▼$11.2052-Week Range$3.46▼$19.00Volume330 shsAverage Volume212,171 shsMarket Capitalization$299.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Oyster Point Pharma alerts: Email Address Ad Porter & CompanyThis military-backed stock “owns” AI marketThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About Oyster Point Pharma Stock (NASDAQ:OYST)Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.Read More Ad Porter & CompanyThis military-backed stock “owns” AI marketThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. OYST Stock News HeadlinesMay 29, 2024 | markets.businessinsider.comaTyr Pharma Buy Rating: Novel Treatment’s Market Potential and Financial UpsideMay 25, 2024 | nypost.comThe 32 best beach reads for summer 2024May 25, 2024 | benzinga.comVersant Vantage I GP-GP, LLC's Net WorthMay 22, 2024 | benzinga.comVersant Vantage I, L.P.'s Net WorthMay 16, 2024 | msn.comCT unveils the first ‘Oyster Trails' map for restaurants, farms and retailMay 16, 2024 | markets.businessinsider.comMaintained Buy Rating on EyePoint Pharmaceuticals Amid Positive Outlook for EYP-1901 in Wet AMDMay 15, 2024 | markets.businessinsider.comStrong Buy Rating for NewAmsterdam Pharma on Obicetrapib’s Promising Efficacy and Market PotentialMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for EyePoint Pharmaceuticals Amidst Positive Duravyu Trial Insights and Future ProspectsMay 8, 2024 | sfgate.comEyePoint Pharmaceuticals: Q1 Earnings SnapshotMay 7, 2024 | markets.businessinsider.comDeep Dive Into EyePoint Pharmaceuticals Stock: Analyst Perspectives (4 Ratings)May 6, 2024 | marketwatch.comEyePoint Pharmaceuticals Trial of Duravyu in Diabetic Eye Disease Fails to Meet Primary EndpointMay 6, 2024 | marketwatch.comEyePoint Pharmaceuticals Shares Slide 32% on Duravyu Trial Missing Primary EndpointMay 1, 2024 | msn.comRestored Texas oyster reef aims to revitalize Galveston Bay after difficult seasonApril 26, 2024 | msn.comWhy Big Pharma Is Following Novartis' Lead In A $25 Billion MarketApril 26, 2024 | theguardian.comReal Americans by Rachel Khong – the lottery of lifeApril 19, 2024 | bizjournals.comAs biotech vacancies hit 20%, oversupply of space could crunch crossover developersApril 15, 2024 | nytimes.comThe 25 Best Restaurants in Boston Right NowApril 3, 2024 | msn.comPortions of Mobile Bay reopen for oyster harvestingMarch 29, 2024 | msn.comThe world is indeed your oyster at the beach in all kinds of waysMarch 28, 2024 | msn.comThe 10 Best Oyster Restaurants In AtlantaMarch 28, 2024 | msn.comBroad Street Oyster Co.’s Legendary Lobster Rolls Land at Ghirardelli Square TomorrowMarch 24, 2024 | msn.comWhat’s the Best Substitute for Oyster Sauce? We Have 10 Tasty SwapsMarch 9, 2024 | sports.yahoo.comSophomore Bussiere shines in net for Oyster River/Portsmouth in state championship lossMarch 6, 2024 | yahoo.comAww shucks!!! Oyster recycling program reaches major milestoneMarch 5, 2024 | uk.finance.yahoo.comBiotechnology Licensing Deals Analysis Reveals Key Trends and Major Agreements from 2019-2024See More Headlines Receive OYST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oyster Point Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today6/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:OYST CUSIPN/A CIK1720725 Webwww.oysterpointrx.com Phone609-382-9032FaxN/AEmployees303Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($6.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,660,000.00 Net Margins-901.99% Pretax Margin-901.99% Return on Equity-490.33% Return on Assets-108.29% Debt Debt-to-Equity Ratio8.49 Current Ratio3.35 Quick Ratio3.11 Sales & Book Value Annual Sales$24.54 million Price / Sales12.22 Cash FlowN/A Price / Cash FlowN/A Book Value$3.80 per share Price / Book2.94Miscellaneous Outstanding Shares26,844,000Free Float22,039,000Market Cap$299.85 million OptionableNot Optionable Beta1.31 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Jeffrey Nau MMS (Age 47)Ph.D., Pres, CEO & Director Comp: $962.85kMr. Daniel Lochner M.B.A. (Age 40)CFO & Chief Bus. Officer Comp: $642kMr. George Donato M.B.A.Sr. VP of CMC & OperationsDr. Eric Carlson Ph.D.Chief Scientific OfficerArty AhmedVP of Investor relationsMr. Barry Rosenfeld J.D.Sr. VP & Gen. CounselMs. Raegan A. McClain CCEPJ.D., L.L.M., Chief Compliance & Privacy OfficerMs. Karen Castillo-PaffVP of Communications & PRMr. Dave BenadonChief HR OfficerMs. Loni Da Silva M.S.Sr. VP of Regulatory AffairsMore ExecutivesKey CompetitorsFreeline TherapeuticsNASDAQ:FRLNAurinia PharmaceuticalsNASDAQ:AUPHAutolus TherapeuticsNASDAQ:AUTLImmaticsNASDAQ:IMTXMesoblastNASDAQ:MESOView All Competitors OYST Stock Analysis - Frequently Asked Questions How were Oyster Point Pharma's earnings last quarter? Oyster Point Pharma, Inc. (NASDAQ:OYST) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.48. The business earned $17.94 million during the quarter. Oyster Point Pharma had a negative net margin of 901.99% and a negative trailing twelve-month return on equity of 490.33%. During the same quarter last year, the company posted ($0.63) earnings per share. What other stocks do shareholders of Oyster Point Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oyster Point Pharma investors own include OPKO Health (OPK), Pfizer (PFE), Akero Therapeutics (AKRO), Walt Disney (DIS), Energy Transfer (ET), Fulcrum Therapeutics (FULC), Johnson & Johnson (JNJ), Occidental Petroleum (OXY) and vTv Therapeutics (VTVT). When did Oyster Point Pharma IPO? Oyster Point Pharma (OYST) raised $85 million in an IPO on Thursday, October 31st 2019. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Cowen and Piper Jaffray served as the underwriters for the IPO. This page (NASDAQ:OYST) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oyster Point Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.